Medicare Part B Covered ($0 Copay)PANEL-PUL-12

Pulmonary & Respiratory Genetics Panel

Chronic lung disease is not always caused by environmental factors or smoking. Genetic conditions like Alpha-1 Antitrypsin Deficiency (AATD) predispose individuals to accelerated lung tissue breakdown and liver impairment. This panel delivers rapid genomic confirmation to enable lung-sparing lifestyle adjustments and targeted augmentation therapy.

Pulmonary Genes12 Targets

Medicare Part B$0 Copay

Lab ProcessNGS Certified

At-Home KitFree USPS 2-Way

Check If You Qualify

Takes under 2 minutes • 100% Covered under Medicare Part B

Verify $0 Eligibility →

HIPAA 256-Bit Encrypted

Who Should Consider This Screening?

Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:

Diagnosis of COPD or emphysema at an unusually early age (<50 years).

COPD or chronic shortness of breath with little or no smoking history.

Unexplained chronic cough, wheezing, or frequent respiratory infections.

Immediate family member diagnosed with Alpha-1 Antitrypsin Deficiency.

Unexplained bronchiectasis or familial interstitial lung disease.

Biomarkers & Genes Evaluated in this Panel

Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.

Gene Symbol / Name	Clinical Significance	Actionable Impact
SERPINA1Alpha-1 Antitrypsin Protease Inhibitor	The definitive gene for Alpha-1 Antitrypsin Deficiency (PIS, PIZ, and null alleles).	Qualifies eligible patients for enzyme augmentation therapy and rigorous pulmonary function surveillance.
CFTRCystic Fibrosis Transmembrane Conductance Regulator	Assesses atypical adult bronchiectasis, recurrent bronchitis, and mild CFTR-related respiratory disorders.	Informs specialized airway clearance techniques, nebulizer protocols, and targeted CFTR modulators.
SFTPC & ABCA3Surfactant Metabolism and Alveolar Integrity	Linked to familial idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases.	Supports early high-resolution chest CT monitoring and antifibrotic medication timing.

Sample Report & Diagnostic Action Plan

Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.

Sample Result ClassificationPathogenic Variant Identified

Identified Finding:

SERPINA1 Genotype: PI*MZ (Carrier of the severe Z deficiency allele with moderate serum reduction).

Clinician Recommendation:

Recommend baseline spirometry, avoidance of all aerosol irritants, and prompt medical treatment for lower respiratory infections.

Medicare Part B Coverage Guidelines

Understand how federal CMS medical necessity guidelines apply to this specific diagnostic screening:

Covered 100% When Medically Necessary

Covered by Medicare Part B when ordered by a licensed physician for patients displaying symptoms of chronic obstructive pulmonary disease or family history of AATD.

Our network of state-licensed physicians reviews your medical profile to confirm eligibility before any kit is mailed.

$0 Out-of-Pocket for Qualifying Seniors

Ready to Check Your Eligibility for Pulmonary & Respiratory Genetics Panel?

Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed

Start 2-Minute Pre-Qualification →